Fora Capital, LLC Bei Gene, Ltd. Transaction History

Fora Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$248.56 - $389.34 $291,063 - $455,917	-1,171 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $292,281 - $472,076	1,171 New	1,171 $425,000
Q3 2020 Nov 13, 2020	SELL	$189.18 - $286.44 $607,456 - $919,758	-3,211 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $397,842 - $627,461	3,211 New	3,211 $605 Million
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $388,425 - $552,129	-3,188 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $369,106 - $664,187	3,188 New	3,188 $528,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.